OTIC Otonomy Inc.

3.25
-0.15  -4%
Previous Close 3.40
Open 3.45
Price To book 0.66
Market Cap 98486083
Shares 30,303,410
Volume 982,522
Short Ratio 0.81
Av. Daily Volume 1,828,832

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released August 30 failed to meet primary and key secondary endpoints.
OTO-104 AVERTS-1
Ménière's disease
Phase 2 trial to be initiated 2H 2017.
OTO-311
Tinnitus
Phase 3 development suspended following failure of AVERTS-1 trial - August 30, 2017.
OTO-104 AVERTS-2
Ménière's disease
Phase 2 trial completed October 2016. Phase 3 trial planned.
OTIPRIO
Pediatric patients with acute otitis media with tympanostomy tubes (AOMT)
Phase 2 trial initiation announced January 19, 2017.
OTO-104
Prevention of hearing loss in cancer patients undergoing chemotherapy
Approved December 11, 2015
OTIPRIO (ciprofloxacin otic suspension)
Ear Tube Placement Surgery
Phase 3 trial met primary endpoint - January 5, 2017. PDUFA date for sNDA filing March 2, 2018.
OTIPRIO
Acute otitis externa

Latest News

  1. Otonomy Provides Business and Financial Update
  2. OTONOMY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Otonomy, Inc. To Contact The Firm
  3. ETFs with exposure to Otonomy, Inc. : August 31, 2017
  4. Otonomy Shares Rebound After Wednesday's Drop- Biotech Movers
  5. Why Otonomy Inc (OTIC), Dycom Industries, Inc. (DY) and Mondelez International Inc (MDLZ) Are 3 of Today’s Worst Stocks
  6. Biotech Nears Zero On Dizzying Plunge After Failed Vertigo Trial
  7. Why H&R Block, Dycom Industries, and Otonomy Slumped Today
  8. Here's Why the Market Is Eviscerating Otonomy Inc. Stock Today
  9. The Long and Short of Biotech Stocks
  10. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of Commencement of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Otonomy, Inc.
  11. Otonomy Shares Fall On Disappointing Phase 3 Data - Biotech Movers
  12. Why Otonomy Shares Are Getting Absolutely Crushed
  13. Otonomy's ear disease drug fails late-stage study
  14. Otonomy Reports Results for AVERTS-1 Phase 3 Trial for OTIVIDEX™ in Patients with Ménière's Disease
  15. Otonomy, Inc. :OTIC-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017
  16. Otonomy, Inc. – Value Analysis (NASDAQ:OTIC) : August 21, 2017
  17. Implied Volatility Surging for Otonomy, Inc. (OTIC) Stock Options
  18. Otonomy, Inc. breached its 50 day moving average in a Bearish Manner : OTIC-US : August 10, 2017
  19. Otonomy Reports Second Quarter 2017 Financial Results and Provides Corporate Update